NASDAQ · TTRX
Healthcare · Biotechnology
$12.49
Down-$0.77 (-5.81%)
Updated Sep 27, 2026, 9:14 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
TTRX closed at $12.49 after 19 trading sessions, up 30.10% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $13.24 | $13.68 | $12.30 | $12.49 | 89.95K |
| Sep 24, 2026 | $13.50 | $13.8799 | $12.065 | $13.26 | 244.96K |
| Sep 23, 2026 | $15.30 | $15.65 | $13.50 | $13.51 | 101.58K |
| Sep 22, 2026 | $15.31 | $15.435 | $14.53 | $15.29 | 122.65K |
| Sep 21, 2026 | $15.05 | $15.555 | $13.59 | $15.34 | 172.96K |
| Sep 18, 2026 | $13.80 | $16.45 | $13.80 | $14.94 | 929.98K |
| Sep 17, 2026 | $13.65 | $14.50 | $13.65 | $13.82 | 199.9K |
| Sep 16, 2026 | $13.46 | $14.21 | $13.40 | $13.72 | 150.4K |
| Sep 15, 2026 | $13.37 | $13.85 | $13.215 | $13.46 | 85.17K |
| Sep 14, 2026 | $12.43 | $13.82 | $12.11 | $13.45 | 131.46K |
| Sep 11, 2026 | $13.30 | $14.25 | $12.63 | $12.69 | 135.66K |
| Sep 10, 2026 | $13.34 | $14.2899 | $13.03 | $13.38 | 125.08K |
| Sep 9, 2026 | $12.61 | $14.39 | $12.58 | $13.75 | 277.54K |
| Sep 8, 2026 | $9.99 | $12.6786 | $9.82 | $12.66 | 321.76K |
| Sep 4, 2026 | $9.975 | $10.50 | $9.70 | $9.80 | 70.57K |
| Sep 3, 2026 | $9.67 | $10.4999 | $9.67 | $10.07 | 82.47K |
| Sep 2, 2026 | $9.70 | $10.25 | $9.00 | $9.67 | 106.48K |
| Sep 1, 2026 | $9.60 | $10.285 | $9.28 | $9.82 | 43.21K |
| Aug 31, 2026 | $9.83 | $10.25 | $9.50 | $9.60 | 31.64K |
The latest Smart Investors Daily articles mentioning TTRX.
TTRX research
Company profile and research snapshot.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Sep 14, 2026 | WBB Securities | Sell | — |
| Mar 24, 2026 | D. Boral Capital | Buy | — |
| Jan 20, 2026 | D. Boral Capital | Buy | — |
| Dec 29, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 24, 2026
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $24.
Benzinga · Sep 14, 2026
WBB Securities analyst Karen Sterling downgrades Turn Therapeutics (NASDAQ:TTRX) from Hold to Sell and announces $10 price target.
Yahoo · Sep 10, 2026
WESTLAKE VILLAGE, Calif., September 10, 2026--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum as follows:
Yahoo · Sep 9, 2026
WESTLAKE VILLAGE, Calif., September 09, 2026--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today announced the appointment of Robert R. Redfield, M.D., as Chief Scientific Officer.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TTRX.
